Amgen Inc

Amgen's capital structure is highly leveraged, with a debt-to-equity ratio of 10.57, indicating a significant reliance on debt financing. The company maintains a liquidity position with a current ratio of 1.26, but its net cash position is negative after subtracting total debt, signaling potential liquidity constraints. The price-to-book ratio of 31.15 and price-to-tangible-book ratio of 31.15 suggest that the market is valuing the company's intangible assets at a premium. Profitability metrics for Amgen are mixed. The company's return on equity (ROE) of 12.59% is strong, but its return on assets (ROA) of 0.82% is significantly below the industry average, indicating inefficient use of assets to generate profit. The gross profit margin of 61.4% is robust, but the operating margin of 22.76% and net margin of 8.89% suggest high operating and non-operating expenses. Amgen's revenue is concentrated in a few key therapeutic areas, with oncology, hematology, and inflammation being the primary drivers. The company's geographic exposure is primarily in North America, with a smaller presence in Europe and Asia. This concentration may expose Amgen to regional regulatory and market risks. The company's growth trajectory is expected to remain stable, with revenue growth projected to be modest in the current fiscal year and the following year. Amgen's free cash flow of $699 million and operating cash flow of $3.15 billion provide some flexibility for reinvestment or debt reduction. Amgen faces several risk factors, including the potential for dilution, which is currently assessed as low. The company's high debt-to-equity ratio and negative net cash position after debt suggest a medium liquidity risk. Additionally, the company's reliance on a few key products and therapeutic areas increases its exposure to product-specific risks. Recent events, including analyst estimates and price targets, indicate a generally positive outlook for Amgen. The mean price target of $355.66 and median price target of $355.00 suggest that analysts expect the stock to appreciate. The mean recommendation of 2.58, with 4 strong-buy ratings and 12 buy ratings, further supports this positive sentiment.